Avidity is pursuing accelerated approval for del-zota in the U.S.

CureDuchenne was an early funder of Avidity, and today we share an important milestone: Enrollment is now complete for the EXPLORE44-OLE clinical trial. Avidity is pursuing accelerated approval for del-zota in the U.S., with plans to file a Biologics License Application (BLA) by the end of the year.

Stay tuned—top-line data from the EXPLORE44® Phase 1/2 trial will be shared next month.

Learn more: https://aviditybiosciences.investorroom.com/2025-02-27-Avidity-Biosciences-Reports-Fourth-Quarter-2024-Financial-Results-and-Recent-Highlights